Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)
NCT03812263Phase 2Completed
- Sponsor
- Rocket Pharmaceuticals, Inc.
- Start
- Aug 2019
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 3
01
Overview
A Phase 2 trial of marnetegragene autotemcel in leukocyte adhesion deficiency type I (LAD-I), sponsored by Rocket Pharmaceuticals, Inc.. Started Aug 2019; status: completed.
02
Drugs
marnetegragene autotemcel
03
Conditions
leukocyte adhesion deficiency type I (LAD-I)
Beyond the preview
Go deeper on NCT03812263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812263.